Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating CellsMichael Timaner, Yuval Shaked, Nitzan Letko-Khait et al.|Cancer Research|2018Cited by 103
Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose ChemotherapyYuval Shaked, Robert S. Kerbel, Santosh Hariharan et al.|Cancer Research|2016Cited by 58
Host effects contributing to cancer therapy resistanceOfrat Beyar‐Katz, Yuval Shaked|Drug Resistance Updates|2014Cited by 44
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib TherapyOfrat Beyar‐Katz, Yuval Shaked, Ksenia Magidey et al.|Molecular Cancer Research|2019Cited by 34
Bortezomib‐induced pro‐inflammatory macrophages as a potential factor limiting anti‐tumour efficacyOfrat Beyar‐Katz, Yuval Shaked, Ksenia Magidey et al.|The Journal of Pathology|2016Cited by 25